Neurocrine Biosciences Inc Revenue Growth Rates (NBIX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Neurocrine Biosciences Inc   (NASDAQ: NBIX)
 

NBIX's Revenue Growth by Quarter and Year

Neurocrine Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NBIX/growth
https://api.csimarket.com/api/v1/companies/NBIX/fundamentals
https://api.csimarket.com/api/v1/companies/NBIX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
NBIX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1,122.70
2nd Quarter June 959.00
1st Quarter March 814.50
FY 2,896.20

NBIXs Annual Revenue
Neurocrine Biosciences Inc 's Revenue in the fiscal year 2025 $ 2,860.50 millions
Neurocrine Biosciences Inc 's Revenue in the fiscal year 2024 $ 2,355.30 millions
Neurocrine Biosciences Inc 's Revenue in the fiscal year 2023 $ 1,887.10 millions
Neurocrine Biosciences Inc 's Revenue in the fiscal year 2022 $ 1,488.70 millions
Neurocrine Biosciences Inc 's Revenue in the fiscal year 2021 $ 1,133.50 millions




NBIX Revenue third quarter 2026 Y/Y Growth Comment
Neurocrine Biosciences Inc reported Revenue rise of 41.24% year on year in the third quarter 2026, to $ 1,122.70 millions, this is lower than Neurocrine Biosciences Inc 's recent average Revenue surge of 201.27%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 24 other companies have achieved higher Revenue growth. While Neurocrine Biosciences Inc ' s Revenue jump of 41.24% ranks overall at the positon no. 580 in the third quarter 2026.


NBIX Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 41.24 %
2nd Quarter June 39.49 %
1st Quarter March 42.25 %
FY   -

Financial Statements
Neurocrine Biosciences Inc 's third quarter 2026 Revenue $ 1,122.70 millions NBIX's Income Statement
Neurocrine Biosciences Inc 's third quarter 2025 Revenue $ 794.90 millions Quarterly NBIX's Income Statement


NBIX Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 17.07 %
2nd Quarter June 17.74 %
1st Quarter March 1.12 %
FY (Year on Year)   -


Back to NBIX Growth rate Comparisons >> Back to NBIX Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #25
Healthcare Sector #138
Overall #580

Revenue Y/Y Growth Statistics
High Average Low
7987.14 % 201.27 % -100 %
(Dec 31 2019)   (Dec 31 2013)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #25
Healthcare Sector #138
Overall #580
Revenue Y/Y Growth Statistics
High Average Low
7987.14 % 201.27 % -100 %
(Dec 31 2019)   (Dec 31 2013)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Neurocrine Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
859.34 % 38.38 % -100 %
(Sep 30 2017)  


NBIX's III. Quarter Q/Q Revenue Comment
Neurocrine Biosciences Inc achieved in the III. Quarter 2026 below company average Revenue jump of 17.07% quarter on quarter, to $ 1,122.70 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 15.62% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Neurocrine Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 552.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #104
Overall #552
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #104
Overall #552
Revenue Q/Q Growth Statistics
High Average Low
859.34 % 38.38 % -100 %
(Sep 30 2017)  


NBIX's III. Quarter Q/Q Revenue Comment
Neurocrine Biosciences Inc achieved in the III. Quarter 2026 below company average Revenue jump of 17.07% quarter on quarter, to $ 1,122.70 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 15.62% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Neurocrine Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 552.


Neurocrine Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 3,701.70
Y / Y Revenue Growth (TTM) 37.98 %
Year on Year Revenue Growth Overall Ranking # 718
Seqeuential Revenue Change (TTM) 9.72 %
Seq. Revenue Growth (TTM) Overall Ranking # 2188


Cumulative Revenue growth Comment
Although Neurocrine Biosciences Inc 's Annual Revenue growth year on year were below company's average 63.48% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 37.98% year on year, from 34.42% in Jun 30 2026.

In the Healthcare sector 157 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 620 to 718.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 37
Healthcare Sector # 158
Overall # 718

Revenue TTM Y/Y Growth Statistics
High Average Low
539.85 %
 63.48 %
-26.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 37
Sector # 323
S&P 500 # 2188
Cumulative Revenue growth Comment
Although Neurocrine Biosciences Inc 's Annual Revenue growth year on year were below company's average 63.48% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 37.98% year on year, from 34.42% in Jun 30 2026.

In the Healthcare sector 157 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 620 to 718.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 37
Healthcare Sector # 158
Overall # 718

Revenue TTM Y/Y Growth Statistics
High Average Low
539.85 %
63.48 %
-26.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 37
Sector # 323
S&P 500 # 2188




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NBIX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions


About Neurocrine Biosciences Inc Revenue Growth Rates (NBIX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Neurocrine Biosciences Inc (CIK 914475).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000914475-26-000054
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Neurocrine Biosciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.